India, June 2 -- Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy in patients with prostate-specific membrane antigen or PSMA-positive metastatic hormone-sensitive prostate cancer or mHSPC.
The company said it plans to present results at an upcoming medical meeting. Based on the feedback from the U.S. Food and Drug Administration, results will be submitted for regulatory review in the second half of the year.
Pluvicto is an intravenous radioligand therapy or RLT that combines a targeting compound with a therapeutic radionuclide. Pluvicto is already approved for metastatic castration-resistant prostate canc...